Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

Stopped Study terminated prematurely by sponsor for business reason. One patient was enrolled.

Conditions

• Hepatocellular Carcinoma

Interventions

• DRUG: Prolarix (tretazicar co-administered with caricotamide)

Sponsor

BTG International Inc.